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Abstract
All living cells perform DNA replication through a group of enzymes called DNA
polymerases. Unfortunately, DNA is constantly exposed to external and internal agents capable of
causing damage. DNA damage causes blocks to replication that can be overcome through a special
class of DNA polymerases, called the Y-family polymerases; which are able to traverse DNA
lesions. Cisplatin is a common chemotherapeutic agent that damages DNA and has been used to
treat cancer. However, many patients become resistant to cisplatin. The chemoresistance to
cisplatin treatment is due in part to damage bypass performed by the specific Y-family polymerase,
polymerase eta. The potential role of Y-family DNA polymerases in the pathway of
chemotherapeutic resistance offers a novel target for inhibition.
To cultivate this thesis, I will provide a brief introduction of cancer and how DNA plays a
role in the development of the disease. I will then discuss the various types of DNA damage and
how they affect the replication process resulting in mutagenesis. Following that, I will begin
discussing several types of repair processes that our cells have adopted to tolerate DNA damage.
This will lead me to hone in one specific mechanism called translesion synthesis, and discuss how
through the recruitment of a special class of DNA polymerases called the Y family polymerases
allows for DNA replication to continue without fixing the damage, and how this plays a role in
chemotherapeutic resistance. From this I will get into the specifics of my project, centered on DNA
polymerase eta’s role in cisplatin resistance which led to implementation of a high-throughput
screening assay to identify potential small molecule targets against Y-family polymerase eta. I
will conclude by summarizing the overall significance of the work done, and discuss research work
that is currently being done on the inhibition of Y-family polymerases, as well as conclude with
what future work can be done regarding this project.
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Introduction
Since the beginning of humanity, cancer has plagued life in all forms.1 Ancient civilization
art and writings have reported cancer in South America, Asia and Egypt. Presently, the disease
affects all species of higher animals.1 In the United States, cancer is one of the leading causes of
human death with approximately 1500 deaths a day.2 In ancient civilizations, malignant
transformations were likely attributed to the work of the gods. It was not until the Middle Ages, it became
apparent that cancer was either inherited or a result of environmental exposure.1 Today, it is commonly
accepted that many cancers are not inherited and that tumor formation is a result of cumulative exposure to
a multitude of environmental agents.1 Epidemiological studies have supported this idea and show
incidences of cancer related to geography and environment, rather than genetic influences. 1 Associations
between environmental agents and incidences of cancer are very strong. One example is exposure to UVradiation given off by the sun.1 Exposure to it results in the formation of bulky thymine-dimer lesions that
interfere with the replication process of DNA.1

Cancer can be the result of the production of a cell that is no longer restrained by normal
growth control mechanisms.3 Chemicals that can effect these cellular changes to yield cancer or
malignant cells are called carcinogens.3 One of the primary targets of chemicals in living
organisms is the genetic material called DNA.3 DNA is the hereditary material essential to all
living cells and encodes for all of the organisms’ essential functions.4 Carcinogens alter the DNA
of the target cell, causing either the replication of DNA to stop (cell death) or undergo mutations
(mistakes) while copying the DNA base sequences.4 When expressed, these error-containing DNA
sequences may then produce cells with inappropriate responses to normal growth control
restraints.4
It is now understood that modification of DNA is the initial step in the progression of tumor
formation. The initiation stage involves DNA damage that alters the DNA’s coding ability. If the
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lesions are not repaired in an error-free manner, replication across these lesions can be highly
mutagenic.4 The resulting altered DNA sequence created by the replication across these lesions is
further “fixed” by the replication machinery.4 The altered sequence of DNA when expressed
produces proteins and cells with altered function that progress into cancer.4
DNA Damage and Repair
Cancer cells do not possess the normal signals that regulate the cell cycle.4 Unlike normal
cells in culture, they do not stop dividing when growth factors are depleted. They are able to elude
normal cell cycle regulation and divide unchecked resulting in the formation of a tumor. 4
Moreover, cancer cells can go on dividing indefinitely if sufficient nutrients are present, essentially
making them immortal.4 This is due in part to the cells being able to evade the normal controls
that trigger a cell to undergo apoptosis when something goes wrong in the cell-cycle process such
as an irreparable mistake during the DNA synthesis stage.4,8 It is now understood that modification
of DNA is the initial step in the progression of tumor formation.4,8 The initiation stage involves
DNA damage that alters the DNA’s coding ability.10 If the lesions are not repaired in an error-free
manner, replication across these lesions can be highly mutagenic.10 The resulting altered DNA
sequence created by the replication across these lesions is further “fixed” by the replication
machinery.10 The altered sequence of DNA when expressed produces proteins and cells with
altered function that progress into cancer.4,10
Before we can examine how DNA is mutated by carcinogenic damage, we must first
understand the chemical structure of the molecule.7,10 The genetic material of all life forms
consists of a macromolecule called deoxyribonucleic acid (DNA).8 DNA is a polymer, a large
molecule that consists of many smaller molecules called monomers linked together. The
monomers that make up DNA are called nitrogenous bases.8 The four nitrogenous bases that make
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up DNA are adenine, cytosine, guanine and thymine, denoted by the letters A, C, G and T. 8 The
bases are held together via hydrogen bonds; intermolecular force that is strong enough to stably
hold together DNA strands, yet easy to break.8 Overall, the structure of DNA (Figure 1) resembles
a double helix, with a sugar phosphate backbone on the outside of the helix and the nitrogenous
bases orientated towards the central axis.8 DNA carries the instructions for an organism to develop,
survive, and reproduce.8
The replication of DNA is vital to a cell’s survival. When DNA
replication occurs, the strands of the DNA double helix separate, the
hydrogen bond breaks at the central axis, (figure 1) and a new
complementary strand of DNA is synthesized on each of the two parental
template strands.9 These newly synthesized strands of DNA are termed
daughter strands, and are identical to the original strand.9 DNA replication
is an intricate process that is carried out in a series of controlled steps.9
The first step to occur is the unwinding of the DNA double helix. This is
done by an enzyme called helicase, whose purpose is to cleave the
hydrogen bonds between the DNA base pairs.9 Once the bonds are broken
and the strands are separated, each strand serves as a template guide for
the insertion of a complementary set of bases on the strand being
synthesized (figure 1).9 The new deoxynucleoside triphosphates (dNTP)

Figure 1. Structure of DNA
double helix, and illustration of
replication.

are added in a specific orientation. The incoming dNTP is covalently linked to the 3’ carbon on
the pentose as the second and third phosphates are removed together as a molecule of
pyrophosphate.9 The nucleotides are added in a way so that a purine always pairs with a pyrimidine
and vice versa meaning that adenine is always inserted across a thymine and guanine is inserted
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across from a cytosine.9 This cellular process is carried out by a large biomolecule, called DNA
polymerase.9
The DNA polymerase binds to one strand of the DNA and reads along it in a 3’5’
fashion, adding new nucleotides in a 5’3’ manner.9 The DNA template can only be synthesized
in a 5’3’ manner, therefore when it reaches the other template strand that is orientated in a 3’5’
manner, a second DNA polymerase comes in and begins synthesizing the DNA in small fragments
that are later joined together by an enzyme called ligase.9 This process of DNA replication is an
extremely accurate process with an error rate as low as 1 out of every 1010 bases.11 The high
fidelity of these enzymes is the result of several contributing factors: the intrinsic ability of the
replicative polymerases to select the correct nucleotide, their ability to recognize and excise
misincorporated nucleotides, and the activity of post-replicative mismatch repair.11 However, the
features that contribute to their high fidelity, also make them extremely sensitive to damage. If the
DNA replication process is occurring, and the polymerase encounters a lesion caused by a
carcinogen, in most cases it will not continue to synthesize, therein inhibiting replication, forcing
the cell down the pathway of apoptosis.9, 11
A carcinogen is any substance, both natural and synthetic, which promotes carcinogenesis,
the formation of cancer.12 Chemical carcinogens are responsible for most cancer deaths in the
United States.2 There are two major classes of chemical carcinogens that are currently recognized.
Direct-acting carcinogens are chemicals that bind to DNA and act as mutagens. The second class
are procarcinogens, which must be converted metabolically to become active carcinogens which
then bind to DNA and act as mutagens.9 There are several key characteristics that contribute to a
substance being carcinogenic. The first characteristic is that the substance is electrophilic and or
can be metabolically activated to become an electrophile. Electrophiles are electron-seeking
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molecules that commonly form addition products, referred to as adducts, with cellular
macromolecules including DNA, RNA and proteins.12 Some examples of direct-acting
electrophilic carcinogens include sulfur mustards and ethylene oxide. Some examples of
procarcinogens that need to be metabolically activated to cause damage include polycyclic
aromatic hydrocarbons, aromatic amines, N-nitrosamines, aflatoxins, and benzene. These
molecules all have the ability to form adducts on nucleic acids and proteins which is a common
property of inherent electrophilic and or metabolically activated human carcinogens. 12
A second characteristic commonly seen in carcinogens is that they are genotoxic, which
means that they are able to induce DNA damage, mutation, or both. DNA damage can be
spontaneous from the source via errors of nucleic acid metabolism or can be induced by
endogenous or exogenous agents.12 In some cases the exogenous agents may also be generated
endogenously, such as formaldehyde and acetaldehyde and UV radiation, producing a background
level of DNA damage.12 Examples of DNA damage include: DNA adducts, which occurs when a
molecule is bound covalently to DNA, DNA strand breaks which are breaks in the phosphodiester
bonds, DNA crosslinks which occur when a chemical agent reacts with to nucleotide bases and
forms a covalent bond between them, and DNA alkylation.12 The DNA damage by itself is not a
mutation and generally does not alter the linear sequence of the nucleotide bases in the DNA.12 A
mutation is a change in the DNA sequence and usually arises as the cell attempts to repair the
DNA.9,12
A third characteristic is the ability of the substance to alter DNA repair mechanisms or
causes genomic instability.12 Normal cells avoid detrimental mutations by replicating their
genomes with high precision.12 However, this precision of the replication process can vary
depending on which polymerase is involved, introducing the possibility of error.12 The nature of
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the error, the flanking sequence, the presence of DNA damage, and the ability to correct errors all
affect the outcome of this process.12 As a consequence, defects in processes that determine DNAreplication fidelity can confer strong mutator phenotypes that result in genomic instability.12 Thus,
carcinogens may act not only by producing DNA damage directly, but also by altering the
processes that control normal DNA replication or repair of DNA damage.12 Examples include the
inhibition of DNA repair by cadmium and formaldehyde. 12
There are three stages involved in chemical carcinogenesis (figure 2).13 These are defined
as initiation, promotion and progression. Each of these stages is characterized by morphological
and biochemical modifications and result from genetic and/or epigenetic alterations.13,14 These
genetic modifications include: mutations in genes that control cell proliferation, cell death and
DNA repair for example, mutations in proto-oncogenes and tumor suppressing genes.14 The first
stage of carcinogenesis is called initiation which is caused by irreversible genetic changes which
predisposes normal cells to transform into malignant cells.14 The normal cell is not yet neoplastic
or in other words does not possess the ability to divide more than they should or lack the ability to
die, but has taken its first step towards this.13-15 The cell has undergone mutations that induce
proliferation but not differentiation.13-15 DNA damage has been well established as the event which
kick-starts chemical carcinogenesis.13 Initiation is a rapid, irreversible phenomenon, and cellular
proliferation is essential for this stage.13-15 If cellular division occurs before DNA repair systems
can carry out their process, then the injury becomes permanent and irreversible.13-15 Initiation is
an additive process, neoplastic development depends on the carcinogenic dose, increasing the dose
increases the incidence and the multiplicity of resultant neoplasia and reduces the latent period of
its manifestation . 13-15
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The second stage is the promotion, which is when cell proliferation in susceptible tissues
continues and enhances alterations in genetic expression resulting in changes in cellular growth
control. 13-16 Cells are only affected in this stage if they have already been stimulated to divide, are
undifferentiated, and have survived apoptosis, so they can contribute to the instability between
growth and cell death which leads to neoplasia.
carcinogenesis is progression.

13-16

13-16

The third and most prominent stage in

Progression is characterized by irreversibility, genetic

instability, faster growth, invasion, metastasis and changes in the biochemical, metabolic and
morphological characteristics of cells. Angiogenesis, the development of new blood vessels to
supply nutrients to the newly growing cells, is essential to neoplastic progression.

13-16

The

acquisition of an angiogenic phenotype precedes the development of characteristics that contribute
to malignancy and its inhibition delays neoplastic development. 13-16

Figure 2. Chemical carcinogenesis stages and the occurrences involved
in each one.

Due to the importance of DNA replication, the maintenance and integrity of our DNA is
crucial. However, as mentioned before he DNA within our cells is constantly being damaged by
chemicals, and the avoidance of carcinogens is almost impossible.17,18 To combat the cellular
damage our cells have developed several repair mechanism to fix and or tolerate the damage to
allow cellular process to continue. There are two general categories of repair systems based on
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the way that thy function.9 The first are direct reversal repair systems which correct damaged areas
by reversing the damage these types of repairs are carried out by mismatch repair carried out by
DNA polymerases and the repair of UV-induced pyrimidine dimers through photoreactivation.9
The second category involves excision repair systems that excise out the damaged area and then
repair the gap by new DNA synthesis. One common type of excision repair is base-excision repair.9
Direct reversal mismatch repair is carried out by DNA polymerase proofreading. Base-pair
substitution mutations occur every 10-7 to 10-11 per generation.9 However, DNA polymerases insert
an incorrect nucleotide at a frequency of 10-5.9 The difference between the mutation rate, and the
incorrect nucleotide incorporation rate can be attributed to the 3’-to 5’ exonuclease proofreading
domain within the polymerase.9 When an incorrect nucleotide is inserted, the proof-reading
domain detects the mismatched basepair and corrects the area by backtracking to remove and
replace the wrong nucleotide and then continue on with the synthesis.9 Base excision repair occurs
when the DNA damage only affects one of the two strands. In these cases, the damage can be cut
out and the undamaged strand can be used as a template for the insertion of a correct nucleotide. 9
There are two common types of excision repair.9 The first is base excision repair, which occurs
when a repair glycosylase enzyme removes the damaged base from the DNA strand by cleavage
of the bond between the base and the deoxyribose sugar.9 Following that, more enzymes will be
recruited in to cleave the sugar-phosphate backbone before and after the now base-less sugar,
resulting in a gap in the DNA strand.9 This gap is filled with the correct nucleotide complementary
to the template strand via a DNA repair protein and DNA ligase.9
However some lesions are large enough that block the replication machinery from
proceeding past the lesion because of the compact nature of the catalytic active site of most DNA
polymerases.18 If the replicative machinery stalls, and cannot proceed on past the lesion it can
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become lethal.18 In order to prevent cellular apoptosis from constantly occurring whenever a bulky
lesion is detected cells undergo damage tolerance using a mechanism called translesion synthesis
(TLS).

18

TLS utilizes specialized DNA polymerases to bypass the damage, which normal DNA

polymerases cannot do, they allow cells to cope with unrepaired DNA damage by promoting
replication through lesions.18 What makes these TLS polymerases unique compared to the normal
replicative enzymes is that they possess enlarged active sites that are capable of accommodating
the damaged or distorted templates.17-18 However, the use of the proteins is often a last-resort
effort because they are extremely error prone and carry an increased risk of mutagenesis. 17,18 The
increased risk of mutagenesis is due in part to the damaged bases are often non- or mis-instructional
of the genetic code and because the structural adaptations that allow lesion replication also result
in reduced fidelity when copying undamaged DNA.17,18
Humans have four Y-family DNA polymerases – Pol , Pol , Pol , and Rev1 – each with
a unique DNA damage bypass and fidelity profile.17,18 Pol, for example, is unique in its ability
to replicate through Ultraviolet (UV) light induced cross-linked DNA.17,18

Because of the

involvement of Pol  in promoting error-free replication through UV-induced cross-links, its
inactivation in humans causes the variant form of xeroderma pigmentosum, a genetic disorder
characterized by a greatly enhanced predisposition to sun-induced skin cancers.17,18 Pol , on the
other hand, is specialized for replicating DNA damaged with the carcinogen found in cigarette
smoke benzo[a]pyrene.17,18 Presumably, the differences in the ability of Y-family polymerases to
replicate across specific lesions are a result of differences in structure. 18,19
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The Y-family polymerases all possess an overall
right-handed configuration similar to the normal
replicative enzymes (Figure 3).19 The ‘palm’ domain
contains the key carboxylate residues needed for
catalysis, but what differentiates them from other
replicative enzymes is that they possess a much larger
active site pocket that can accommodate bulky or
distorted DNA templates.19

The fingers and thumb

domains used to detect and select the fit of the incoming
nucleotides are typically shorter in these Y-family

Figure 3. Crystal Structure of Y Family Polymerase Eta.
The main domains are color coded (palm = red, thumb =
green, finger = blue, exonuclease (Exo) = purple,
amino-terminal domain (N) = yellow).

19

polymerases, and make fewer contacts with both the
template and incoming nucleotide contributing to the reduced fidelity observed in these
molecules.19 Another unique feature that the Y-family polymerases possess is a little finger
domain, most often referred to as the polymerase-associated domain (PAD), that provides stability
when replicating the DNA.19 The most critical feature that Y-family polymerases lack is a 3’5’
proof-reading exonuclease domain which is what results in an extremely error prone replicative
process, with error incorporation rates of up to one in ten nucleotides.19 However, the mutations
induced through this mechanism are less harmful than the potentially lethal alternative of an
incompletely replicated DNA strand.19
My area of research focuses on the TLS polymerase protein, DNA polymerase eta (pol
η).20,21 DNA pol η, is one of the best characterized translesion synthesis polymerases. 20,21 It has
been shown that pol η is specifically optimized for bypassing the most profound type of DNA
lesion, cyclobutane pyrimidine (CPD) dimers caused by UV radiation of sunlight. 20,21 The damage
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caused by ultraviolet radiation catalyzes covalent linkages between adjacent pyrimidines in DNA,
which results in dimers which create roadblocks to most DNA polymerases. 20,21 Human pol η is
able to perform replication past these bulky thymine dimers because of its larger active site that
can accommodate the DNA lesion distortion. 20,21 Pol η is the only one of the fifteen human DNA
polymerases in which defects are unequivocally associated with cancer.11 Research has shown that
humans who have a defective POLH gene, which encodes pol η, are effected by a variant form of
human xeroderma pigmentosum syndrome (XPV). 20,21 XPV is an inherited disorder caused by a
deficiency in human pol η and is typically associated with an increased occurrence of sunlightinduced skin cancers. 20,21
More recently the Y-family polymerases have been gaining interest because of their
potential involvement in chemotherapeutic resistance.21 DNA damaging chemotherapy is typically
the first line of treatment for certain cancers, such as testicular and colorectal cancers.21 One
common type of chemotherapy is carried out with the use of genotoxic agents. These types of
drugs either bind to DNA or indirectly damage DNA by affecting enzymes involved in replication,
and ultimately leading to induced apoptosis.22 This type of treatment is effective at targeting the
disease because proliferating cancer cells undergo replication and division at a much higher rate
than healthy cells.22 There are several types of genotoxic compounds used for treatment; including
alkylating agents, enzyme inhibitors and intercalating agents.22
Enzyme inhibitors work by blocking replication and inhibiting enzymes involved in the
process. One example of enzyme inhibitors used are topoisomerase I inhibitors that interfere with
strand separation during DNA replication.22 Enzyme inhibitors are less frequently used because
their mutagenic properties make them carcinogenic and open the door for the potential of
developing secondary cancers.22 Alkylating agents work by altering the nucleotides within DNA
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resulting in an interference with DNA replication and transcription leading to mutations within the
genetic code.22 Alkylating agents work by reacting with the proteins that bond together to form
the very delicate double helix structure of a DNA molecule, adding an alkyl group to some or all
of them.22 This prevents the proteins from linking up as they should, causing breakage of the DNA
strands and, eventually, the death of the cancer cell.22 Some examples of alkylating agents include
nitrogen mustard, alkyl sulfonates, and triazines. Intercalating agents bind within the groves of the
DNA helix and interfere with polymerase activity during replication and transcription.22
While DNA damaging chemotherapy can be very effective and even curative in the
treatment of certain cancers, intrinsic and acquired drug resistance underlies tumor progression
and morbidity in many cancer patients.23 Intrinsic resistance defines a cell state that is inherently
tolerant of drug action.23 This can include the activation of drug efflux pumps or detoxifying
processes that effectively reduce intracellular drug concentration.23 This can also include a change
in the recognition or persistence of DNA damage, mediated by an enhanced DNA repair capability,
a blunted DNA damage response, or the ability to proliferate in the presence of DNA damage.23
Mutagenic TLS polymerases underlie two important phenotypes in response to genotoxic
chemotherapy.23 First, they allow for the bypass of modified DNA bases during DNA synthesis,
allowing proliferation to continue in the presence of chemotherapy.23 Second, the low fidelity
replication performed by TLS polymerases results in the introduction of inappropriate, non-pairing
bases across from modified nucleotides.23 The bypass function of TLS polymerases is particularly
relevant to intrinsic drug resistance.23 Many tumors, including most pancreatic adenocarcinomas,
non-small cell lung cancers, and aggressive brain tumors, as well as most metastatic malignancies,
fail to significantly regress following chemotherapy.23 In these tumors, TLS activity contributes to
a drug resistant state by promoting the tolerance of DNA damage.23
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One chemotherapeutic drug that has shown high-rates of chemotherapeutic resistance is
Cisplatin, or cis-diamminedichloroplatinum (II). It is a well-known chemotherapeutic drug that
has been used for treatment of numerous human cancers including bladder, head and neck, lung,
ovarian, and testicular cancers.21,24 It is also effective against various types of cancers, including
carcinomas, germ cell tumors, lymphomas, and sarcomas.21,24 The most abundant DNA adduct
arising from the reaction between cisplatin and DNA is the intrastrand cross-link between two
guanines (Pt−GG) (figure 4).21,24

Figure 4. Cisplatin binding to dGTP forming a PT-GG intrastrand and interstrand crosslinks.

These cross-links on the DNA; interfere with DNA repair mechanisms, causing DNA
damage, and subsequently inducing apoptosis in cancer cells. 21,24 Though not as cytotoxic as
interstrand cross-links, intrastrand cross-links must still be repaired and/ or bypassed.24 In this
regard, human DNA pol η seems to be an important player in the tolerance of unrepaired
intrastrand cross-links generated by platinum drugs.24 However, cancer cells are employing TLS
to tolerate the damage caused by the treatment, rendering it ineffective. Research has linked pol η
as the main culprit behind cisplatin resistance because the cisplatin–cross-linked guanines (Pt-GG)

15

are structurally similar to the cyclobutane pyrimidine dimers (CPD) induced by UV radiation
(figure 5).21

Figure 5. Structures of a thymine dimer (CPD)
15
and a Pt-GG lesion.

Kinetic assays have revealed that kinetic analysis revealed that pol η copies the 3′-dG and
5′-dG sites of a Pt−GG adduct with catalytic efficiencies of 82 % and 35%, respectively relative
to unmodified DNA, meaning that it has an affinity for successfully replicating past these bulky
cross-links compared to a normal nucleotide within the DNA strand.24 Another study found that
cells derived from xeroderma pigmentosum variant (XPV) patients that do not express functional
pol η are considerably more susceptible to cisplatin treatment than cells that express proficient
levels of pol η.24
Crystal structures have revealed that pol-η can accommodate a bulky Pt-GG DNA crosslink
within its active site cleft without any major rearrangement of the enzyme.21 The specificity of
human pol η for a Pt-GG, compared to other DNA polymerases, derives from an active site cleft
that is sufficiently open to allow near perfect Watson-Crick geometry of the Pt-GG-dCTP
(cytosine) base pair, but is also to accommodate the inclined 5′ guanine of Pt-GG without any
steric hindrance.24 The pol η active site cleft is well poised for catalysis and the incorporation of
cytosine opposite the 3′ guanine of Pt-GG (Figure 6).21 Thus, even though Pt-GG is a larger and
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more distorted intrastrand crosslink than a cis-syn thymine–thymine dimer, it does not lead to any
substantial agitation of the human pol η active site or affect the ability of the polymerase to carry
out replication.21 The primer terminus is well aligned for the incorporation of cytosine opposite
the 3′ guanine of the Pt-GG adduct allowing replication to continue past the lesion.21 Inhibition of
pol η may potentially reduce chemoresistance to platinum-based drugs caused by translesion DNA
synthesis.21,24

Figure 6. The structure of human Pol-η in ternary complex with
the cisplatin intrastrand cross-link (PtGpG) DNA and the
incoming dCTP. The PtGpG is shown in gray and blue, and the
incoming dCTP is shown in red. The putative Mg2+ ion is shown
21
in dark blue.

Potential inhibitor screening assay against Y-family polymerases
A strand-displacement assay is currently being used as a technique to analyze pol η activity
with various potential inhibitors. The way the strand displacement assay works is based on
fluorescent reporter strand displacement from a tripartite (three part) substrate containing a
quencher-labeled template strand, an unlabeled primer and a fluorophore-labeled reporter.25 The
idea behind it is that if the polymerase is functioning, it will begin to incorporate nucleotides on
to the free 3’ end of the primer, and as this is occurring it will displace the fluorescent reporter
away from the quencher giving off a fluorescent signal.25 The degree of fluorescent signal is
directly proportional to enzyme concentration, and activity. As you increase the protein’s
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concentration, the level of activity, in this case DNA replication will increase resulting in an
increase of fluorescence. So in the presence of an inhibitor, the level of fluorescence would
decrease as a result of enzyme inhibition which is what makes this assay useful in screening for
compounds. Currently, this method is being employed on another y-family polymerase, DNA
polymerase kappa, and several compounds have been found to have inhibitory effects on its
activity.25 The identification of several compounds against polymerase kappa is what provided us
a starting point to begin looking for potential inhibitors of pol η.
A study conducted by Woodgate et al. identified three
compounds that had significant inhibitory effects on polymerase
Kappa. The three that they identified were Ellagic acid, Pamoic Acid,
and Aurintricarboxylic acid (figure 6).25 Ellagic acid (EA) is a
naturally occurring polyphenolic compound which is found in many
fruits, nut galls and plant extracts in the forms of hydrolysable tannins
called ellagitannins such as raspberries, strawberries, grapes,
pomegranate, black currants, mango, guava, walnuts, almonds,
longan seeds and green tea.26 It is a highly thermostable molecule that

Figure 7. The structure of the
compounds used in the current
study.

is slightly soluble in water, alcohol, and ether. Structurally, presents four rings representing the
lipophilic domain, four phenolic groups and two lactones, which form hydrogen-bonds sides and
act as electron acceptors respectively, and that represent the hydrophilic domain.26 Evidence
suggests EA’s mode of action is that binds covalently to DNA and induces DNA single-strand
breaks and inhibits the replicative and repair synthesis of DNA.26
Pamoic acid (4-[(3-carboxy-2-hydroxynaphthalen-1-yl methyl]-3-hydroxynaphthalene2-carboxylic acid) has been used in formulations of several drugs as pamoate salts. 27 It is
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commonly used pharmaceutical salt pamoic acid to activate GPR35, an orphan G protein-coupled
receptor (GPCR but has been identified as a potential inhibitor of polymerase Kappa through
unknown mechanisms.27 The third compound, Aurintricarboxylic acid showed the strongest
inhibitor effect against pol kappa. Aurintricarboxylic acid can be prepared by the condensation of
formaldehyde with salicylic acid in the presence of nitrite-containing sulfuric acid.28 Its mode of
inhibition is believed to be due to the fact that it readily polymerizes in aqueous solution, forming
a stable free radical that inhibits protein-nucleic acid interactions such as the interaction between
DNA polymerases and the DNA base.28
The goal of this project was to incorporate the high-throughput screening assay described
above to identify additional l drug inhibitors against pol η. The first step was to transform the gene
that encodes for pol η into a competent, Escherichia coli (E.coli) cell line and grow the bacterium
up using the technique of recombinant protein expression. Once protein of interest, pol η, was
expressed, it needed to be purified. Protein purification is vital for the characterization of the
function, structure, and interactions of proteins. The various steps in the purification process may
include cell lysis, separating the soluble protein components from cell debris, and finally
separating the protein of interest from product- and process-related impurities using various types
of chromatography. The results from this research lead to the optimization of the stranddisplacement assay to screen for inhibitors for pol η. Ellagic acid was found to have a potential
inhibitory affect against pol η.
Methodology
Protein Expression of Polymerase Eta (Pol η)
Recombinant protein expression is performed by placing the gene that encodes the pol η
protein into a host organism that will be used to grow the protein. Wild-type pol η was obtained
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using standard E. coli protein expression. The plasmid DNA that encodes for pol η was obtained
from Dr. Penny Beuring’s lab at Northeastern University. The plasmid was designed to work on
the lactose operon repression system. The lactose operon is found naturally in E. coli, and when
genetically engineered into a plasmid it contains a specific sequence ahead of the gene of interest,
in this case pol η, to which a protein repressor can bind. The repressor averts transcription factors
and RNA polymerase from binding to the plasmid DNA and inhibiting the production of the
protein.29 Utilizing a lactose-operon system, E. coli can be induced using isopropyl-β-D
thiogalactopyranoside (IPTG) to control its expression of the gene of interest. 29 The IPTG binds
to the repressor, causing a conformational change that removes the repressor from the DNA.29
Once the repressor is away from the DNA, pol η can be transcribed and translated into protein.
This technique is used to ensure a high yield of protein expression.
The plasmid was also manipulated so that pol η was expressed fused to multiple histidines
and a glutathione S-transferase (GST) tag at the end terminal of the protein. The GST-histidine tag
(his-tag) serves purpose for use in affinity chromatography, a method of purification used to extract
proteins from cell lysates. In addition to taking advantage of the lactose operon and his-tag, the
plasmid containing pol η contained a gene for kanamycin resistance. Kanamycin is a broadspectrum antibiotic that causes breakdown of the cell wall of bacteria. Bacteria that do not have
resistance to the antibiotic will not grow in culture. Therefore, the kanamycin resistance gene is
expressed actively to prevent the growth of unwanted organisms and to allow for the selection of
E. coli cells that have successfully taken up the pol η plasmid.
The Pol η plasmid was transformed in BL21-Gold E. coli. The cells were streaked for
single colonies onto an LB Agar plate, and grown overnight at 37°C. A single colony containing
genetically pure E. coli was grown in 10 mL sterile TY Medium broth overnight with shaking. The
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resulting growth was divided into four 1 L flasks of sterile TY Medium broth, and grown at 37°C
with shaking to an absorbance of 0.6 at 595 nm. The absorbance reading indicated sufficient
growth for Pol η production. The flasks were cooled to 18°C and induced with IPTG, and left to
shake overnight to produce Pol-η. The next day, the 4 L of broth and E. coli were centrifuged at
4°C for 35 minutes at 5000 RPM, respectively, to pellet the E. coli cells containing the protein of
interest, Pol-η.
Extraction of Pol-η from Escherichia coli Cells
The cell pellet was resuspended in a buffer solution (Buffer A) containing 50 mM Tris (pH
8.0), 300 mM NaCl, 20mM imidazole, 10% glycerol, 10mM 2-mercaptoethanol. Protease inhibitor
cocktail tablet was added to prevent degradation of Pol η. The resuspended cells were sonicated
with high frequency sound waves to lyse open the cell wall and extract the protein. Sonication
cycle is as follows: 10 second burst, 30 second break, 10 second burst. This process was repeated
4 times, with a 2 minute break in between each cycle, to ensure proper cell lysis. Following
sonication the cell solution was spun-down using an ultracentrifuge. The cells were spun at
18,000RPM for 40 minutes to pellet the cellular debris, and collect Pol η in the lysate.
Purification of Pol η
The purification of Pol η was achieved through a two-step process using a GE Healthcare
sciences 5mL HisTrap Column with fast protein liquid chromatography (FPLC), following a
Biorad gravity glutathione Sepharose column to obtain pure, untagged wild-type Pol η.
Affinity Chromatography
Nickel columns are used for immobilized metal affinity chromatography (IMAC) for the
purification of recombinant proteins that contain a histidine tag. The histidine residues in the tag
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bind to the vacant positions in the coordination sphere of the immobilized nickel ions in the
column.30 When the filtered lysate is loaded on the column, the His-tagged protein is bound and
other unwanted proteins pass through the column matrix.30 In the case of column chromatography
two buffers are used, typically denoted as buffer A and buffer B. Buffer A is used as a wash buffer
to ensure proper purification of the protein is achieved, and no unwanted proteins remain, then
Buffer B is used as an elution wash to strip the protein of interest from the column. In the case of
nickel chromatography, Buffer B contains a high imidazole concentration to strip the protein from
the column. Imidazole is a chemical that structurally similar to that of the histidine molecule, so at
high concentrations, it will compete for the empty positions in the nickel ions, essentially forcing
the histidine tags out, releasing it from the column.30 All washes during the column are collected
in fractions for analysis.
Fast Protein Liquid Chromatography (FPLC)
Fast protein liquid chromatography (FPLC) is a form of medium-pressure chromatography
that uses a pump to control the speed at which the mobile phase passes through the stationary
phase.31 In terms of this experiments, the stationary phase was the nickel column, and the mobile
phases were Pol n, followed by buffer A and buffer B. FPLC systems generally consist of a pump,
a UV detector, a conductivity meter, and a fraction collector and operate at pressures of ~3,500 psi
(24 MPa).31 As the system is running, a chromatograph is generated to visualize the purification
in real-time. It graphs the UV absorption vs the concentration of elution buffer. Proteins are large
biomolecules that contain several aromatic rings that have the ability to absorb light, an absorption
signal is detected around 280nm when it is eluted from the column.31
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Purification Procedure
The purification of Pol n was run at 4°C. The first step was to prepare the two buffers;
Buffer A and Buffer B. Buffer A contained 50 mM Tris (pH 8.0), 300 mM NaCl, 20mM imidazole,
10% glycerol, 10 mM 2-mercaptoethanol. Buffer B was prepared identically, except instead it had
a 200 mM imidazole concentration to ensure successful elution from the column. Following buffer
preparation the sample, the filtered Pol η lysate underwent a 10-fold dilution, and 200 mL of the
lysate was loaded onto the column. Once the protein was loaded, on to the column, the solution
probes were placed into buffers A and B and a linear gradient wash was carried out by the FPLC.
Fractions were collected and analyzed via SDS gel electrophoresis to identify which fractions
contained Pol η.
SDS-PAGE is a polyacrylamide gel electrophoresis (PAGE) technique that uses sodium
dodecyl sulfate (SDS) to coat proteins with a negative charge. The negative charge allows the
proteins to migrate in an electric current towards a cathode. The polyacrylamide gel slows proteins
in its polymerized matrix, allowing smaller proteins to flow through faster than larger proteins,
thus separating the proteins by molecular weight. A bromophenol blue dye (0.125 M Tris-HCl [pH
6.8], 5 mM EDTA, 15% glycerol, 2% SDS, 1% 2-mercaptoethanol, 0.1% bromophenol blue) is
added to the samples in the gel in order to track the progress through the gel. Once the dye front
has reached the bottom of the gel, the gel is removed and the proteins within are stained with
Coomassie Blue. Pol η can be analyzed in this way by comparing the bands loaded in each lane
with a molecular weight marker. The cell lysate, and the fractions collected from the FPLC were
loaded onto a gel to locate which fractions contained Pol η. All SDS-PAGE was performed using
a Bio-Rad Mini-PROTEAN 3 apparatus with 10% polyacrylamide gels in Tris buffer (diluted from
5X stock - 0.125 M Tris base, 0.96 M glycine, 5.0 g SDS).
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The next step in the purification process was to remove the GST/His-tag from the protein
to prevent any unwanted interactions occurring in future assays. This was done via protein
digestion to cleave the His-tag, and glutathione sepharose chromatography to recover the pureuntagged protein. The fractions containing purified Pol η were pooled together and loaded onto
a GST column, and an enzyme called PreScission Protease was used to digest and cleave the GSTHis-tag from the end terminal of the protein. PreScission Protease is a genetically engineered
enzyme made up of human rhinovirus 3C protease and GST (Viljanen, Larsson, and Broo; 2008).
The enzyme’s protease domain site-specifically cuts between the Gln and Gly residues of
LeuGluValLeuPheGln/GlyPro, a peptide sequence cloned in between GST and pol η. Pol η and
precision protease was left to incubate in the column overnight to ensure cleavage and proper
binding of the GST tag to the matrix of the column. The following day, the flow through, which
should only contain untagged Pol η, was collected by FPLC and visualized via SDS- gel
electrophoresis.
Quantification of Pol η
To determine the concentration of protein that was purified a Bradford assay was
performed. The principle of this method is based on the proportional binding of the dye Coomassie
Brilliant Blue-G250 to proteins.32 Within the linear range of the assay, the more protein present,
the more Coomassie binds.32 Furthermore, the assay is colorimetric; as the protein concentration
increases, the color of the test sample becomes darker.32 Coomassie Blue dye absorbs at 595 nm.
The protein concentration of a test sample is determined by comparison to that of a series of protein
standards known to reproducibly exhibit a linear absorbance profile in this assay.32 The protein
standard that was used Bovine Serum Albumin (BSA).
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Five standard solutions of BSA were prepared with deionized water in clear plastic cuvettes
with the following concentrations; 2 µg/mL, 4 µg/mL, 6 µg/mL, 8 µg/mL, and 10 µg/mL. Biorad
Coomassie Brilliant Blue-G250 dye reagent was added, and the mixture was inverted and then
incubated for five minutes. After the incubation period the absorbance was taken at 595nm using
the spectrophotometer. This experiment was run in triplicate, and the absorbance values of each
trial were recorded.
The preparation of samples to determine the concentration of Pol η was down by a guess
and check method. Several solutions with “X µL” of Pol η were pipetted and put into “x µL”
amount of dH2O so that the total volume was 800uL, and then 200µL of dye was added to bring
the volume to 1mL. After adding the dye, the samples were left to incubate at room temperature
for 5 minutes, and then the absorbance was taken at 595nm. If the absorbance value did not fit
within the range, then a new sample of protein was made according to the rule that if the absorbance
reading was too high, then a more dilute sample was made, if it read too low, then a more
concentrated solution was made until it fit the range. Once an absorbance value was detected that
fit within the standard range, it was plotted on the graph to determine the concentration.
Polymerase Fidelity Assay
To determine if the Pol η that was purified is active, a polymerase fidelity assay, called the
primer-template extension was executed. Template-primer insertion is accomplished in vitro by
creating a synthetic DNA template substrate, with a 4 nucleotide overhang on the template stand
and a free 3’OH group on the end of the primer that will allow for nucleotide incorporation
complementary to the template when nucleotides and polymerase η are added (Figure 8). The
products of the reaction will be separated and visualized using denaturing polyacrylamide gel
electrophoresis, and visualized using a laser imager.
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Figure 8. Diagram of the polymerase fidelity assay nucleotide incorporation.

The DNA substrate used was a 13-mer primer/ 18-mer template pair from Integrated DNA
Technologies with a 5’-CY5 fluorophore for visualization in a polyacrylamide gel. The reaction
conditions were as follows: 20 nM Pol η, 200nM oligonucleotides, 100 μM dNTP (deoxynucleotide), 25 mM MgCl2, 250 mM Tris-HCl (pH 8.0), 200 mM NaCl, and 10 mM dithiothreitol
(DTT). The final volume of each mixture was 10 µL. The reactions took place at room temperature
for 30 minutes, and then were stopped with bromophenol blue in deionizing formamide. The
reaction products were separated using a 40% polyacrylamide gel. The reaction products of Pol η
synthesis across from the 18-mer template were visualized using a Bio-Rad Pharos FX plus
Molecular Imager and Bio-Rad Quantity One software. The activity of pol η was tested on a time
scale, ranging from 30 seconds up until 30 minutes. Human pol η was incubated with the DNA
substrate and nucleotides (dNTP’s), and then the reaction was quenched at the desired time
intervals to view the activity of the polymerase.
Strand-Displacement Assay
The strand-displacement assay was also used in an attempt to identify potential drug
inhibitors of DNA pol η. The way the strand displacement assay works is based on fluorescent
reporter strand displacement from a tripartite (three part) substrate containing a quencher-labeled
template strand, an unlabeled primer and a fluorophore-labeled reporter.14 The idea behind it is
that if the polymerase is functioning, it will begin to incorporate nucleotides on to the free 3’ end
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of the primer, and as this is occurring it will displace the fluorescent reporter away from the
quencher giving off a fluorescent signal (figure 9).

Figure 9. Strand displacement DNA synthesis assay. F and Q denote 6-TAMRA and
Black Hole Quencher-2 (BHQ-2), respectively. Chemical structures of 6-TAMRA and
BHQ-2 used in the present study are also provided.

14

The strand displacement assay was run in a 96-well plate using a time scale ranging from
0 seconds up until 50 minutes to view the activity of pol η. The reactions were prepared in 96 well
plates. The reaction conditions were as follows: ‘X’ nM Pol η, 770mM DNA substrate mix, 400
μM dNTP (deoxy-nucleotide), 25 mM MgCl2, 250 mM Tris-HCl (pH 8.0), 200 mM NaCl, and 10
mM dithiothreitol (DTT). X= (50 nM, 100 nM, 200 nM Pol η). All reactions were quenched with
EDTA, and fluorescence data was recorded using a microplate reader set to a 525nm excitation
and 595 emission.
Strand displacement assays run to test for inhibitor were run in 96 well plates under the
following conditions;100 nM Pol η, 770mM DNA substrate mix, 400 μM dNTP (deoxynucleotide), 25 mM MgCl2, 250 mM Tris-HCl (pH 8.0), 200 mM NaCl, and 10 mM dithiothreitol
(DTT) and ‘X’ amount of inhibitor compound. X= (20µM- 200µM concentration range).
Compounds tested were Ellagic acid, Pamoic Acid, and Aurintricarboxylic acid all from Sigma
Aldrich. The reactions were incubated at room temperature and quenched with EDTA after 35
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minutes. Plates were then analyzed, and fluorescence data was recorded using the microplate
reader set to 525nm excitation and 595nm emission.
Results
Protein Expression, Purification and Quantification.
Several rounds of protein expression and purification were performed as needed to obtain
large, homogenous amounts of pol η. Figure 10 shows the SDS-PAGE gel of the fractions
collected from the FPLC nickel Histrap purifications. Purified pol η was present in lanes 8-12
around the 77 kDa mark as expected. The chromatograph generated from the UV detector during
FPLC purification is shown in Figure 11. The peaks present at 280nm indicate homogenous
protein coming off of the column.
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Figure 10. SDS-PAGE gel for determining the purity of Pol η.
Lane MW- molecular weight marker (labeled in kDa). Lane 1-12
fractions collected from FPLC purifications. Pol η was found in
lanes 8-12 at ~77kdA.

Figure 11. Chromatograph generated during FPLC
purification. The presence of protein is indicated by
the two peaks at 280nm. The X-axis depicts the
volume of buffer eluted, and the Y-axis depicts the
relative absorbance in mAU.
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Figure 12 shows the SDS-PAGE of the protein digest to get visual confirmation that
precision protease cleaved the tag off of pol η. The presence of two bands indicates one belonging
to pol η and the other to the GST/His-tag. Figure 12 shows the SDS-PAGE of pure untagged polη.
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55-
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40
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3333-

24-
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Figure 12. SDS-PAGE gel of protein digest (left) and Pol η after
GST Column (right). Lane 1 (left) shows two bands present
indicating successful cleavage of the tags. Right- Lane 1 displays
the flow through containing untagged Pol η after protein digestion,
at ~48kDa.

A plot of absorbance verses concentration was made and the linear standard curve was
determined to have an equation of y= 0.0638x +.0394, with an R2 value of .9996. The standard
curve generated from the Bradford assay to determine the concentration can be found in figure 13.

Absorbance @
595nm

0.8
0.6
0.4

y = 0.0638x + 0.0394
R² = 0.9996

0.2
0
0

2

4

6

8

10

12

Concentration BSA (µg/mL)
Figure 13.Standard curve generated from the average absorbance of
the BSA standards. Equation y = 0.0638x + 0.0394 R² = 0.9996.
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Using the equation generated from the standard curve above, the concentration of purified pol η
was determined to be 900ug/mL or .188mM of pol η.
Single-Base Nucleotide Primer Assay
One polymerase assay was successfully performed to determine nucleotide incorporation
by pol η. The assay was run over the course of 30 minutes, with quenching of the reaction at 1
minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 25 minutes and 30 minutes. The results can
be seen in Figure 14. Despite the poor gel resolution, shifted bands can be seen in lanes 5, and 6
indicating nucleotide incorporation by DNA pol η. The bands underneath the DNA starting
template band indicate impurities within the DNA substrate. It can be visualized that full extenstion
onto the primer was obtained at 25 minutes.

Figure 14. Primer template extension assay over the course of 30 minutes. The red arrow indicates the start
of the primer. The red arrow indicates the primer band of the primer. Nucleotide incorporation above the
primer can be seen starting at 5 minutes, and full extension is reached at 25minutes. The banding shown
underneath is due into impurities in the DNA substrate.

Strand Displacement Assay
To determine the optimal protein concentration for our strand displacement assay, varying
concentrations of pol η were tested while keeping other parameters constant. The strand
displacement assay was run in a 96-well plate using a time scale ranging from 0 seconds up until
50 minutes to view the activity of pol η. This experiment was carried out using three different
concentrations of protein: 50 nM, 100 nM, and 200 nM pol η. The results can be seen in Figure
15. The black line symbolizes the 50 nM pol η, the blue lines symbolizes the 100 nM pol η, and
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the green line symbolizes the 200nM pol η. Full extension was obtained at around 40 minutes,
indicated by the presence of a plateaued line. Figure 16 displays the data gathered from the strand
displacemnet assay when ellagic acid was introduced into the DNA-polymerase mix. It was
determined that increasing the amount of ellagic acid had an inhibtory effect on pol η enzymatic
activity indicated by a decrease in fluorescence.The graph plots the relative fluorescence against
the log of the inhibitor concentration. Pamoic acid and aurintricarboxylic acid were tested against
pol η in the strand displacement assay but did not demonstrate conclusive results.

Figure 15. Data collected on the microplate reader
presenting various concentrations: 50nM polymerase eta
(black), 100nM pol eta (blue), and 200nM pol eta.

Figure 16. Data collected from the microplate reader
displaying the effects of an increasing concentration
of Ellagic acid on 100nM of pol η after a 35 minute
incubation period, run at 37 °C.

Discussion
The purpose of this work was to implement a real-time reporter-strand displacement assay
for DNA pol η to identify potential inhibitors. Inhibition of DNA repair and replication is an
established approach to treating cancer, as the elevated expression of DNA repair and damage
tolerance proteins can negatively affect patient response to genotoxic drugs.21 As an example, the
Y-family member pol η is overexpressed in the stem cell line of ovarian cancer patients, and this
overexpression decreases the effectiveness of cisplatin, shortening the time to tumor recurrence.
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The ability to slow the development of resistance and increase efficacy could benefit many patients
undergoing chemotherapy with platinum-based drugs.24
In my research I developed a working protocol for the expression and purification of pol
η. The expression and purification was accomplished by producing wild-type protein using
recombinant protein expression techniques, and then programming a purification method on the
FPLC using UnicornTM software. The purity of pol η was determined using SDS-PAGE and the
quantity of pol η was determined using a spectroscopic technique known as a Bradford Assay. I
then characterized the enzymatic activity of pol η by measuring its ability to synthesize DNA. To
do this a template-primer extension assay was used to measure the insertion and extension of pol
η. This was accomplished in vitro by incubating pol η with a fluorescently labelled DNA substrate,
and deoxynucleotides. The template-primer extension assay revealed that pol η was able to
incorporate nucleotides on to the primer, confirming the enzymatic activity of pol η.
High-throughput screening is a scientific methodology that allows for simultaneous testing
for potential drug inhibitors against enzymes of interest. Recently, Llyod et al. has developed a
high-throughput screen towards Y-family DNA polymerases.25 The assay is based on fluorescent
reporter strand displacement from a tripartite substrate containing a quencher-labeled template
strand, an unlabeled primer and a fluorophore-labeled reporter. With this method one can follow
the enzymatic activity of these Y family polymerases by quantify the fluorescence intensity using
a microplate reader. As a first step of incorporating this screening method to identify potential
inhibitors for pol η I performed initial screenings of protein and nucleotides to determine the
optimal parameters for fluorescent responses. This was accomplished in vitro by incubating
varying concentrations of pol η with the fluorescent tripartite DNA substrate and deoxynucleotides
over a course of 45 minutes. Through these initial screenings I determined that 100 nM pol η was
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a suitable protein concentration for the assay and concluded that full extension onto the primer was
achieved at 35 minutes.
With the parameters optimized, I then took to screening the three compounds: ellagic acid,
pamoic acid, and aurintricarboxylic acid. The data collected from these initial screenings is
preliminary, and a further, more exhaustive study needs to be completed, in which the IC50 values
would be calculated. However, from the initial screenings, the only compound out of the three
that had a noticeable inhibitory effect on pol η enzymatic activity was ellagic acid. This result was
expected because a study conducted by Woodgate at el. determined that ellagic acid had a
significant inhibitory effect on pol η’s replicative ability with an IC50 value of 0.062 uM. The data
obtained from screening pamoic acid and aurintricarboxylic acid against pol η, yielded
inconclusive results due to unknown experimental errors. From the data collected, it appeared to
have no significant effect on pol η ability however due to a large variation in the numbers gathered
from the plate reader no final conclusions can be made. More thorough studies would have to be
repeated to make any definite conclusions about the effects of these compounds on Pol eta.
Woodgate at el screened these compounds against pol η and discovered that they both had
inhibitory effects on the polymerases activity. They identified that pamoic acid did not have as
large of an effect on pol η activity as ellagic acid did, inhibiting the activity at around 70 uM.
Whereas the aurintricarboxylic acid had a simialr potency to that of ellagic acid, with an IC50 value
of 0.075uM.25
Zafar at el. is currently using the strand displacement assay to research the effect of
derivatives from N-aryl-substituted indole barbituric acid (IBA), indole thiobarbituric acid
(ITBA), and indole quinuclidine scaffolds as potential inhibitors for pol η. Through their studies
they

have

found

that

5-((5-chloro-1-(naphthalen-2-ylmethyl)-1Hindol-3-yl)methylene)-2-
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thioxodihydropyrimidine-4,6- (1H,5H)-dione (PNR-7-02), an ITBA derivative that inhibited pol
η activity with an IC50 value of 8 μM and exhibited 5−10- fold increased specificity for pol η over
replicative polymerases.24 Through molecular docking simulations they hypothesize that PNR-702 binds to a site on the little finger domain and interferes with the proper orientation of template
DNA to inhibit pol η.24
Although the overall goal of identifying compounds that had significant inhibitory effects
on pol η enzymatic activity was not accomplished due to experimental set-backs and time
constraints, I was able to successfully optimize the reaction conditions and propose a working
protocol to monitor the effects of compounds on pol η enzymatic activity to hopefully someday
identify inhibitors. Future work on this product includes screening a large library of compounds
using this strand displacement assay to identify hits against pol η. Successful inhibition of pol η
could render platinum-based treatments more effective by eliminating the tumor cell population
largely responsible for tumor relapse and by suppressing the emergence of chemo-resistant tumor
cells.24
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